Structure

InChI Key WZPBZJONDBGPKJ-VEHQQRBSSA-N
Smile C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
InChI
InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H17N5O8S2
Molecular Weight 435.44
AlogP -1.17
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 7.0
Polar Surface Area 201.58
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial penicillin-binding protein inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- 32 - 2000 -
Enzyme Protease
- 3340 - - -
Transporter
- 6 - - -
Unclassified protein
- 60 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Bacterial Infections 4 D001424 ClinicalTrials
Skin Diseases 3 D012871 ClinicalTrials
Enterobacteriaceae Infections 3 D004756 ClinicalTrials
Gonorrhea 2 D006069 ClinicalTrials
Renal Insufficiency 1 D051437 ClinicalTrials
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

Scaffolds

UNKNOWN

Side Effects from Label

Side effects Relative Frequency (%) Labels
Respiratory, thoracic and mediastinal disorders Cough 54.1
Respiratory, thoracic and mediastinal disorders Cough
Respiratory, thoracic and mediastinal disorders Nasal congestion 15.8
Respiratory, thoracic and mediastinal disorders Wheezing 15.8
Investigations Body temperature increased 13.0
Respiratory, thoracic and mediastinal disorders Laryngeal pain 12.3
General disorders and administration site conditions Pain 12.0
Respiratory, thoracic and mediastinal disorders Nasal congestion
Respiratory, thoracic and mediastinal disorders Laryngeal pain
Respiratory, thoracic and mediastinal disorders Wheezing
Cardiac disorders Chest discomfort 7.53
Cardiac disorders Chest pain 7.53
Gastrointestinal disorders Abdominal pain 6.85
Gastrointestinal disorders Gastrointestinal pain 6.85
Investigations Alanine aminotransferase increased 6.5
Blood and lymphatic system disorders Eosinophilia 6.3
Cardiac disorders Chest discomfort
Cardiac disorders Chest pain
Gastrointestinal disorders Vomiting 6.16
Investigations Blood creatinine increased 5.8
Investigations Body temperature increased
Gastrointestinal disorders Abdominal pain
Gastrointestinal disorders Gastrointestinal pain
Gastrointestinal disorders Vomiting
Skin and subcutaneous tissue disorders Dermatitis 4.3
Skin and subcutaneous tissue disorders Rash 4.3
Investigations Aspartate aminotransferase increased 3.8
Blood and lymphatic system disorders Thrombocytosis 3.6
Blood and lymphatic system disorders Neutropenia 3.2
Immune system disorders Bronchospasm 3.0
Skin and subcutaneous tissue disorders Erythema 2.9
Vascular disorders Phlebitis 2.1
Skin and subcutaneous tissue disorders Dermatitis 2.0
Skin and subcutaneous tissue disorders Rash 2.0
Gastrointestinal disorders Diarrhoea 1.4
Investigations Body temperature increased 1.0
General disorders and administration site conditions Induration 0.9

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Respiratory, thoracic and mediastinal disorders
25.55
General disorders and administration site conditions
12.5
Infections and infestations
11.67
Gastrointestinal disorders
10.19
Congenital, familial and genetic disorders
7.31
Injury, poisoning and procedural complications
6.6
Surgical and medical procedures
5.52
Cardiac disorders
3.56
Vascular disorders
2.79
Investigations
2.61

Cross References

Resources Reference
CAS NUMBER 78110-38-0
ChEBI 161680
ChEMBL CHEMBL158
DrugBank DB00355
DrugCentral 279
FDA SRS G2B4VE5GH8
Human Metabolome Database HMDB0014499
Guide to Pharmacology 10763
PDB AZR
PubChem 5742832
SureChEMBL SCHEMBL37511
ZINC ZINC000003830264